8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Apr 22, 2020)

Filed April 22, 2020For Securities:BIIB

Summary

Biogen Inc. filed an 8-K on April 22, 2020, primarily to report its financial results for the first quarter ended March 31, 2020. The key information is contained within the press release furnished as Exhibit 99.1, which details the company's operational performance and financial condition. Investors should refer to this press release for specific financial figures, including revenue, earnings per share, and any commentary on business segment performance. This filing serves as a formal notification of the release of quarterly financial data. While the 8-K itself is brief, it directs stakeholders to the comprehensive press release for a full understanding of Biogen's performance during the period. This typically includes updates on product sales, pipeline developments, and management's outlook, which are crucial for assessing the company's trajectory and investment potential.

Key Highlights

  • 1Biogen Inc. announced its first quarter 2020 financial results on April 22, 2020.
  • 2The press release containing detailed financial information is furnished as Exhibit 99.1.
  • 3The filing covers the quarter ended March 31, 2020.
  • 4This 8-K is primarily an informational filing to publicize the quarterly earnings release.
  • 5Investors are directed to the press release for a full understanding of the company's financial performance and condition.
  • 6The information furnished is not deemed 'filed' for Section 18 purposes.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Biogen Inc.'s financial results for the first quarter ended March 31, 2020, through a furnished press release.

The detailed financial results, including revenue, earnings, and other operational data, are available in the press release issued by Biogen on April 22, 2020, which is included as Exhibit 99.1 to this 8-K filing.

This 8-K filing itself does not contain forward-looking statements or guidance. Investors should refer to the press release (Exhibit 99.1) for any such information or commentary provided by Biogen management regarding future expectations.

No, the financial results and the accompanying press release furnished under Item 2.02 are not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to its liabilities.